Comparative Pharmacology
Head-to-head clinical analysis: HYDROGENATED ERGOT ALKALOIDS versus METHYLERGONOVINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROGENATED ERGOT ALKALOIDS versus METHYLERGONOVINE MALEATE.
HYDROGENATED ERGOT ALKALOIDS vs METHYLERGONOVINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrogenated ergot alkaloids act as partial agonists/antagonists at α-adrenergic receptors, serotonergic (5-HT1B/1D) receptors, and dopaminergic receptors. They cause vasoconstriction by activating α-adrenoceptors and 5-HT receptors on vascular smooth muscle, and inhibit prolactin secretion via D2 receptor agonism.
Ergot alkaloid; partial agonist/antagonist at alpha-adrenergic, serotonin (5-HT2), and dopamine receptors; directly stimulates uterine smooth muscle contractions.
1 mg orally three times daily, or 0.3 mg intramuscularly or subcutaneously once daily.
0.2 mg intramuscularly or intravenously once, may repeat as needed every 2-4 hours for a maximum of 5 doses.
None Documented
None Documented
2-3 hours for dihydroergotamine; 12-15 hours for ergoloid mesylates, requiring cautious dosing in hepatic impairment.
Biphasic: initial (alpha) ~10-30 min; terminal (beta) ~2-3 hours in normal subjects; prolonged to ~6-12 hours in hepatic impairment or pregnancy
Primarily hepatic metabolism (70-80%) with biliary excretion; renal excretion accounts for less than 10% of unchanged drug.
Renal (approximately 60-80% as metabolites, <1% unchanged); biliary/fecal (minor route, approximately 20-30%)
Category C
Category D/X
Ergot Alkaloid
Ergot Alkaloid